Cargando…

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis (PsA), a disorder that presents with additional joint inflammation and other clinical features. At present, the mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palfreeman, Andrew C, McNamee, Kay E, McCann, Fiona E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615921/ https://www.ncbi.nlm.nih.gov/pubmed/23569359 http://dx.doi.org/10.2147/DDDT.S32713

Ejemplares similares

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

Clinical potential of apremilast in the treatment of psoriatic arthritis
por: Cauli, Alberto, et al.
Publicado: (2014)

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
por: McCann, Fiona E, et al.
Publicado: (2010)

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2023)

Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink
por: Persson, Rebecca, et al.
Publicado: (2022)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells
por: Notley, Clare A., et al.
Publicado: (2008)

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
por: Liu, Yong, et al.
Publicado: (2014)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2020)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic
por: Das, Ashis K., et al.
Publicado: (2023)

Pediatric psoriasis treated with apremilast
por: Smith, Rebecca L.
Publicado: (2016)

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
por: Pai, Ganesh, et al.
Publicado: (2017)

Correction: Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic
por: Das, Ashis K., et al.
Publicado: (2023)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study
por: Ferguson, Lyn D, et al.
Publicado: (2021)

The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register
por: Jones, Gareth T., et al.
Publicado: (2021)

Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report
por: Gualtierotti, Roberta, et al.
Publicado: (2019)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

DNA methylation patterns in CD4(+) T-cells separate psoriasis patients from healthy controls, and skin psoriasis from psoriatic arthritis
por: Natoli, Valentina, et al.
Publicado: (2023)

GENETICS OF PSORIASIS AND PSORIATIC ARTHRITIS
por: Chandran, Vinod
Publicado: (2010)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2022)

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

From Psoriasis to Psoriatic Arthritis: Insights from Imaging on the Transition to Psoriatic Arthritis and Implications for Arthritis Prevention
por: Zabotti, Alen, et al.
Publicado: (2020)

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey
por: van de Kerkhof, P.C.M., et al.
Publicado: (2015)

Evidence-based modalities in the management of Psoriasis and Psoriatic arthritis
por: Francesco, Chiappelli
Publicado: (2023)

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
por: Mease, Philip J., et al.
Publicado: (2023)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
por: Mease, Philip J., et al.
Publicado: (2014)

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
por: Puig, Lluís
Publicado: (2017)

Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity
por: Ruffilli, Ilaria, et al.
Publicado: (2017)

Recurrence of Melanoma after Starting Apremilast for Psoriasis
por: Salopek, Thomas G.
Publicado: (2017)

Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature
por: Garcovich, Simone, et al.
Publicado: (2020)

Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis
por: Loft, Nikolai Dyrberg, et al.
Publicado: (2018)

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
por: Lebwohl, Mark G., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kgeddjsde44oubs2hvo58amfss